



# Julius Bär

PERFORMANCE REPORT AS OF 31.03.2025

1/4


## JB TRACKER CERTIFICATE ON THE JULIUS BAER NEXT GENERATION GENOMICS INDEX (NTR)

### TERMS

Issuer	Bank Julius Baer & Co. Ltd, Guernsey
Calculation agent	Bank Julius Baer & Co. Ltd, Zurich
ISIN	CH0591004814
Valor	59100481
Initial Fixing Date	22.03.2021
Tenor	open-end


### HISTORICAL PERFORMANCE

Chart Since Inception



### YEARLY PERFORMANCE CHART

Chart Since Inception



### INDEX COMPOSITION (31 MAR 2025)

NAME	ISIN	TICKER	CURRENCY	LAST PRICE	WEIGHT
TAKEDA PHARMACEUTICAL CO LTD	JP3463000004	4502 JT	JPY	4'413.00	4.7%
ALNYLAM PHARMACEUTICALS INC	US02043Q1076	ALNY UW	USD	270.02	3.4%
AMGEN INC	US0311621009	AMGN UW	USD	311.55	11.6%
ARGENX SE	NL0010832176	ARGX BB	EUR	540.60	3.3%
ASTRAZENECA PLC	GB0009895292	AZN LN	GBP	11'254.00	10.8%
AZENTA INC	US1143401024	AZTA UW	USD	34.64	0.1%
BACHEM HOLDING AG	CH1176493729	BANB SE	CHF	51.80	0.2%
BIOMARIN PHARMACEUTICAL INC	US09061G1013	BMRN UW	USD	70.69	1.3%
CHARLES RIVER LABORATORIES	US1598641074	CRL UN	USD	150.52	0.7%
CRISPR THERAPEUTICS AG	CH0334081137	CRSP UQ	USD	34.03	0.3%
QUEST DIAGNOSTICS INC	US74834L1008	DGX UN	USD	169.20	1.8%
SARTORIUS STEDIM BIOTECH	FR0013154002	DIM FP	EUR	182.35	0.5%
GUARDANT HEALTH INC	US40131M1099	GH UW	USD	42.60	0.4%
GILEAD SCIENCES INC	US3755581036	GILD UW	USD	112.05	12.1%
ICON PLC	IE0005711209	ICLR UW	USD	174.99	1.3%
ILLUMINA INC	US4523271090	ILMN UW	USD	79.34	1.2%
IQVIA HOLDINGS INC	US46266C1053	IQV UN	USD	176.30	3.1%
LONZA GROUP AG-REG	CH0013841017	LONN SE	CHF	542.20	4.1%
MEDPACE HOLDINGS INC	US58506Q1094	MEDP UW	USD	304.69	0.7%
MERCK KGAA	DE0006599905	MRK GY	EUR	126.60	1.7%
NATERA INC	US6323071042	NTRA UW	USD	141.41	1.6%
BEIGENE LTD-ADR	US07725L1026	ONC UW	USD	272.17	2.7%
QIAGEN N.V.	NL0015002CX3	QGEN UN	USD	40.15	0.9%
REGENERON PHARMACEUTICALS	US75886F1075	REGN UW	USD	634.23	6.4%
SAREPTA THERAPEUTICS INC	US8036071004	SRPT UW	USD	63.82	0.6%
TECAN GROUP AG-REG	CH0012100191	TECN SE	CHF	166.70	0.2%
THERMO FISHER SCIENTIFIC INC	US8835561023	TMO UN	USD	497.60	8.9%
UCB SA	BE0003739530	UCB BB	EUR	162.75	2.1%
VERTEX PHARMACEUTICALS INC	US92532F1003	VRTX UW	USD	484.82	11.5%
WEST PHARMACEUTICAL SERVICES	US9553061055	WST UN	USD	223.88	1.6%

### FACTS

Price	83.05
Currency	USD
Initial participation	100%

### PERFORMANCE FIGURES

1 month	-11.46%
3 months	4.79%
1 year	-3.93%
since launch	-16.95%
year to date	4.79%
maximum drawdown	42.74%

lifetime high	129.5
lifetime low	74.15
52 week high	94.65
52 week low	78.1

### CERTIFICATE VOLATILITY

1 month	14.50%
3 months	12.91%
1 year	15.46%
since launch	19.07%


## INDEX FACTS &amp; FIGURES

Administrator	Solactive AG
Name	Julius Baer Next Generation Genomics Index NTR
ISIN	DE000SLOCJ43
Rebalancing Frequency	Quarterly
Last Rebalancing	08.01.2025
Last Additions (6)	Alnylam Pharmaceuticals Inc, Argenx SE, Medpace Holdings Inc, Sarepta Therapeutics Inc, UCB SA, West Pharmaceutical Services I
Last Deletions (3)	Wuxi Biologics Cayman Inc, BB Biotech AG, BioNTech SE, Moderna Inc, Twist Bioscience Corp, 10X Genomics Inc


## INDEX PERFORMANCE FIGURES

	MSCI World	Index
1 month	-0.03%	-10.76%
3 months	4.16%	-2.15%
6 months	7.15%	-1.84%
1 year	28.72%	1.47%
since launch (07.07.2017)	103.66%	32.11%
year to date	15.93%	0.01%


## INDEX VS MSCI WORLD (NTR) PERFORMANCE CHART




## INDEX MEMBER PERFORMANCE (SINCE LAST REBALANCING)



## INDEX COMPOSITION



## INDEX MEMBER PERFORMANCE CONTRIBUTION (SINCE LAST REBALANCING)



---

## CONTACTS

---

**Structured Products**

Structured Products PB Sales

+41 (0) 58 888 8006  
 derivatives@juliusbaer.com  
 derivatives.juliusbaer.com

BANK JULIUS BAER & CO. LTD.  
 Bahnhofstrasse 36  
 P.O. Box  
 8010 Zurich  
 Switzerland

**IMPORTANT LEGAL INFORMATION**

This publication constitutes **marketing material** and is not the result of independent financial/investment research. It has therefore not been prepared in accordance with the legal requirements regarding the independence of financial/investment research and is not subject to any prohibition on dealing ahead of the dissemination of financial/investment research. It has been produced by Bank Julius Baer & Co. Ltd., Zurich, which is authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA).

**The information expressed in this publication was produced as at the date of writing and is subject to change without notice.** This publication is intended for **information purposes only and does not constitute advice, an offer or an invitation** by, or on behalf of, Julius Baer to buy or sell any securities or related financial instruments, or to participate in any particular trading strategy in any jurisdiction. Although the information herein is trusted to be accurate and complete, and data herein has been obtained from sources believed to be reliable, no specific representation is made in this respect herein. In particular, the information provided in this publication may not cover all material information on the financial instruments or issuers of such instruments. Julius Baer does not accept liability for any loss arising from the use of this publication. Entities within the Julius Baer Group provide advice that is not considered 'independent' within the meaning given to that term by EU Directive 2014 / 65 / EU on markets in financial instruments (known as MiFID II).

Although the information and data herein are obtained from sources believed to be reliable, no representation is made that the information is accurate or complete. In particular, the information provided in this publication may not cover all material information on the financial instruments or issuers of such instruments. Bank Julius Baer & Co. Ltd., Zurich, its subsidiaries and affiliated companies do not accept liability for any loss arising from the use of this publication. Important sources for the production of this publication are e.g. national and international media, information services (e.g. Reuters, Bloomberg Finance L.P.), publicly available databases, economic journals and newspapers (e.g. Financial Times, Wall Street Journal), publicly available company information, publications of rating agencies. Ratings and appraisals contained in this publication are clearly marked as such.

All information and data used for this publication relate to past or present circumstances and may change at any time without prior notice. Statements contained in this publication regarding financial instruments or issuers of financial instruments relate to the time of the production of this publication. Such statements are based on a multitude of factors which are subject to continuous change. A statement contained in this publication may, thus, become inaccurate without this being published. Potential risk regarding statements and expectations expressed in this publication may result from issuer specific and general (e.g. political, economic, market, etc.) developments.

**SUITABILITY**

Investments in the asset classes mentioned in this publication may not be suitable for all recipients and may not be available in all countries. **Clients of Julius Baer are kindly requested to get in touch with the local Julius Baer entity in order to be informed about the services and/or products available in their country.** This publication has been prepared without taking account of the objectives, financial situation or needs of any particular investor. Before entering into any transaction, investors should consider the suitability of the transaction to individual circumstances and objectives. Any investment or trading or other decision should only be made by the client after a thorough reading of the relevant product term sheet, subscription agreement, information memorandum, prospectus or other offering document relating to the issue of the securities or other financial instruments. **Nothing in this publication constitutes investment, legal, accounting or tax advice, or a representation that any investment or strategy is suitable or appropriate to individual circumstances, or otherwise constitutes a personal recommendation to any specific investor.** Any references to a particular tax treatment depend on the individual circumstances of each investor and may be subject to change in the future. Julius Baer recommends that investors independently assess, with a professional advisor, the specific financial risks as well as legal, regulatory, credit, tax and accounting consequences. Where a publication makes reference to a specific research report, the publication should not be read in isolation without consulting the full research report, which may be provided upon request.

**GENERAL RISKS**

The price and value of, and income from investments in, any asset class mentioned in this publication may fall as well as rise and **investors may not get back the amount invested.** Risks involved in any asset class mentioned in this publication may include, but are not necessarily limited to, market risks, credit risks, political risks and economic risks. The investor may be exposed to **currency risk** when the product or underlyings of the product are denominated in currencies other than that of the country in which the investor is resident. The investment as well as its performance would therefore be exposed to currency fluctuations and may increase or decrease in value. Investments in emerging markets are speculative and may be considerably more volatile than investments in established markets. **Past performance is not a reliable indicator of future results. Performance forecasts are not a reliable indicator of future performance.** Shares, bank debt securities (e.g. interest-bearing bank bonds and certificates) as well as other claims against financial institutions are subject to special regulations, such as the Bank Recovery and Resolution Directive, the Single Resolution Mechanism Regulation and related national laws implementing such special regulations. These regulations can have a negative effect for the investor / contractual partner of the financial institution in case of a default and the necessity of a resolution of the financial institution. For further details, please refer to: [www.juliusbaer.com/legal-information-en](http://www.juliusbaer.com/legal-information-en)

**SPECIFIC RISKS**

**Contingent convertible bonds (CoCo bonds):** Generally, investments in CoCo bonds (which absorb losses if a bank's capitalisation falls below a defined level) for European Economic Area resident clients are only allowed for professional clients; for retail clients, they are generally permitted if the issuer provides a Key Information Document according to the Regulation for Packaged Retail Investment and Insurance-based Products (PRIIPs KID). The German securities regulator (Federal Financial Supervisory Authority, BaFin) does not regard CoCo bonds as a suitable investment for retail clients due to their complex product structure, their intended use, the fact that they are difficult to value and the potential conflict of interests on the part of the bank. Retail clients wishing to purchase CoCo bonds on their own initiative should carefully consider the specific features and risks involved when making their decision. In addition, according to the Product Intervention (Contingent Convertible Instruments and Mutual Society Shares) Instrument 2015, enacted by the UK Financial Conduct Authority (FCA), these products must not be purchased by retail clients domiciled in the European Economic Area (EU, Liechtenstein, Norway and Iceland), unless one of the following conditions is met: annual income of at least GBP 100,000 (or equivalent) or net assets (excluding property, insurance and other benefits) of at least GBP 250,000 (or equivalent) at disposal.

**Structured products** (e.g. baskets, certificates): These are complex financial products and therefore involve a higher degree of risk. They are intended for investors who understand and are capable of assuming all risks involved. Structured products may therefore only be sold to experienced investors and require additional advice regarding the product-specific risks. The value of the products is not only dependent on the development of the underlying, but also on the creditworthiness of the issuer, which may vary over the term of the product. In case of the issuer's insolvency or bankruptcy, the investors in the product may lose their entire investment in the product. Before entering an investment all documents related to the issue of the described structured product have to be read. The full terms of the respective structured product may be obtained free of charge.

**Funds:** Investments in funds mentioned in this publication should only be made after a thorough reading of the current prospectus, the current Key Investor Information Document or simplified prospectus, the fund regulations or articles of association, the latest annual and semi-annual reports or other offering or fund documentation, such as the offering memorandum and subscription form. These documents can be obtained free of charge upon request. Please note that collective investment schemes exclusively open to qualified investors may be fully or partially exempted from producing these documents by the Swiss Financial Market Supervisory Authority (FINMA). Performance values may be calculated without taking account of commissions and costs that result from selling and buying back investments.

#### CONFLICT OF INTEREST

Julius Baer is required to disclose important information about its interests and potential conflicts. In order to prevent conflicts of interest from adversely affecting the interests of its clients, Julius Baer has established a policy and procedures designed to identify and manage such conflicts. These include organisational and administrative arrangements to safeguard the interests of clients, adequate remuneration policies (for persons involved in the production of this publication) based largely on qualitative criteria (e.g. overall quality and accuracy of research) and only remotely on quantitative elements (e.g. overall performance of Julius Baer). A Julius Baer entity may, to the extent permitted by law, participate or invest in other financing transactions with the issuer of the securities referred to herein, perform services or solicit business from such issuers, have a position or effect transactions in the securities or options thereof, have any other significant financial interest regarding the issuers of the securities referred to herein and/or may have done so in the past. For further information about our interest in the investments featured in this publication, see the company-specific disclosures above.

#### IMPORTANT DISTRIBUTION INFORMATION

This publication and any market data contained therein **shall only be for the personal use of the intended recipient** and shall not be redistributed to any third party, unless Julius Baer or the source of the relevant market data gives their approval. This publication is not directed to any person in any jurisdiction where (on the grounds of that person's nationality, residence or otherwise) such publications are prohibited.

**External Asset Managers/External Financial Advisers:** In case this publication is provided to EAMs/EFAs, Julius Baer expressly prohibits that it be redistributed by the EAMs/EFAs or be made available to their clients and/or third parties. By receiving any publication, the EAMs/EFAs confirm that they will make their own independent analysis and investment decisions, if applicable.

**Switzerland:** This publication is distributed by Bank Julius Baer & Co. Ltd., Zurich, authorised and regulated by the Swiss Financial Market Supervisory Authority (FINMA). All investment funds mentioned in this publication are authorised for distribution in Switzerland. Some of the investment funds mentioned in this publication may not be authorised for distribution in Switzerland and may therefore only be distributed to qualified investors as defined in the Swiss Collective Investment Schemes Act and the Swiss Collective Investment Schemes Ordinance. Structured products do not constitute a participation in a collective investment scheme. Therefore, they are not supervised by the Swiss Financial Market Supervisory Authority FINMA and the investor does not benefit from the specific investor protection provided under the Swiss Federal Act on Collective Investment Schemes (CISA). This publication is not a simplified prospectus as stated in Art. 5 of the CISA.

**United States:** NEITHER THIS PUBLICATION NOR ANY COPY THEREOF MAY BE SENT, TAKEN INTO OR DISTRIBUTED IN THE UNITED STATES OR TO ANY US PERSON.

#### THIRD-PARTY INFORMATION

This publication may contain information obtained from third parties, including ratings from rating agencies such as Standard & Poor's, Moody's, Fitch and other similar rating agencies, and research from research providers such as MSCI ESG Research LLC or its affiliates. Issuers mentioned or included in any MSCI ESG Research LLC materials may be a client of, or affiliated with, a client of MSCI Inc. (MSCI) or another MSCI subsidiary. Reproduction and distribution of third-party content in any form is prohibited except with the prior written permission of the related third party. Third-party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information, including ratings or research, and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third-party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third-party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including lost income or profits and opportunity costs) in connection with any use of their content, including ratings or research. Credit and/or research ratings are statements of opinions and are not statements of fact or recommendations to purchase, hold or sell securities. They do not address the market value of securities or the suitability of securities for investment purposes and should not be relied on as investment advice.